Table 2.

Treatment prior to lenvatinib therapy

	LEN monotherapy	LEN combination
First-line treatment	27/69%	62/86%
Second-line treatment	12/31%	8/11%
Sorafenib	12/31%	3/4%
Apatinib	0	3/4%
PD-1 antibody	0	2/3%
Third-line treatment	0	2/3%

Data are presented as n/%

LEN, lenvatinib; PD-1, programmed cell death protein-1